Sint-Lucas General Hospital — Clinical Trial Site

27 Registered trials

9 Currently recruiting

Organisation

Sint-Lucas General Hospital

Location

Brugge, Belgium

Identifier

ORG-100030257

Address

Sint-Lucaslaan 29, 8310, Belgium

Departments

Department of Internal Medicine – Medical Oncology
Department of Nephrology
Department of Urology
Gastro enterology
Gastro-enterology
Gastro-oncology
Gastroenterologie
Gastroenterology
Gynecology-Obestetrics
nephrology
Oncology
Psychiatrie
Psychiatry
Rheumatology
Urology

Clinical trials at this site (27)

Search interface

ABTECT-1 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -1 Not authorised

2022-500535-36-00 Moderately to severely active ulcerative colitis 5
ABTECT-Maintenance – ABX464 Treatment Evaluation for ulcerative Colitis Therapy Not authorised

2022-500537-84-00 Moderately to severely active ulcerative colitis 5
BALLAD Belgium - A trial to evaluate the potential benefit of adjuvant chemotherapy for small bowel adenocarcinoma. The Belgian component of… Pending

2024-518349-85-01 small bowel adenocarcinoma 5
Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combination for Inflammatory Bowel Disease Pending

2025-524640-35-00 Ulcerative colitis (Inflammatory Bowel Disease) 4
Long-term study to assess the safety and tolerability of adjunctive NBI-1065845 in adults with Major Depressive Disorder (MDD) Recruiting

2024-519423-24-00 Major Depressive Disorder 5 2025-10-07
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis Recruiting

2025-521242-26-00 Moderately to Severely Active Ulcerative Colitis 4 2025-11-27
Study that aims to investigate how effective and safe the use of a novel modified release tablet formulation of Colesevelam hydrochloride-MM… Recruiting

2024-511993-55-00 bile acid diarrhoea (BAD) 4 2025-09-18
Study to assess the efficacy and safety of adjunctive NBI-1065845 in adults with Major Depressive Disorder (MDD) Recruiting

2024-519421-37-00 Major Depressive Disorder 5 2025-08-28
Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus Trastuzumab Plus or Minus … Recruiting

2024-513122-27-00 Unresectable, Locally Advanced or Metastatic HER2 posit 5 2025-06-10
Treatment of heart and blood vessel disease (cardiovascular disease) with low dose blood thinner (low dose rivaroxaban) in people with advan… Recruiting

2024-512483-59-00 Improvement of cardiovascular outcomes in patients with 5 2023-06-09
Multicenter randomized controlled clinical trial comparing ebastine and mebeverine as treatment of irritable bowel syndrome Recruiting

2022-501780-41-00 Irritable Bowel Syndrome 5 2023-05-17
Prevention of postoperative endoscopic disease recurrence in Crohn’s disease: a multicentric study that compares the systematic start of bio… Recruiting

2022-500311-39-00 Patients with Crohn's disease undergoing surgery and ha 6 2022-09-08
“NALPAC” A NON-COMPARATIVE RANDOMIZED PHASE 2 STUDY, EVALUATING THE EFFICACY OF 5-FU + NALIRI AND 5-FU + NALIRINOX FOR METASTATIC PANCREATIC… Recruiting

2024-516336-97-00 METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA 4 2022-02-21
Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination with Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Part… Ended

2023-506146-23-00 Non-Muscle-Invasive Urothelial Carcinoma (NMIBC) of the 4 2025-11-17
A Study to Investigate the Efficacy and Safety of Solrikitug in Adults with Eosinophilic Esophagitis Ended

2024-510849-34-00 Eosinophilic Esophagitis 4 2025-02-04
Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-200 … Ended

2023-507187-39-00 High-Risk Non-muscle-invasive Bladder Cancer 5 2023-03-23
A study to investigate changes in symptoms and esophageal histology with tezepelumab compared with placebo in patients aged 12 to 80 years o… Ended

2023-504277-20-00 Eosinophilic esophagitis (EoE) is a rare, chronic infla 5 2023-01-30
Effectiveness and Safety of Sparsentan as treatment for Immunoglobulin A Nephropathy (IgAN) Ended

2023-505495-30-00 Immunoglobulin A Nephropathy (IgAN) 5 2019-02-01
A Phase III double-blind placebo-controlled Randomised Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients Ended

2022-502798-40-00 Patients with resected colon carcinoma 5 2017-07-31
A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in … Ended

2024-511057-22-00 Major Depressive Disorder (MDD) with Moderate-to-severe 5 2024-12-04
A study to test different doses of BI 1569912 in people with depression who take anti-depressive medicine Ended

2023-507942-10-00 Major depressive disorder 4 2024-07-31
ABTECT-1 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -1 Ended

2022-500535-36-01 Moderately to severely active ulcerative colitis 5 2023-06-12
"A PHASE 3, MULTICENTER, MULTINATIONAL, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF CC-93538 IN ADULT AND ADOLESCENT SUBJ… Ended

2023-506278-10-00 Eosinophilic esophagitis 5 2022-04-22
Evaluating the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age Ended

2023-508820-37-00 Cytomegalovirus Infection (CMV) 5 2022-02-03